Development, Implementation and Evaluation of a Clinical Practice Guideline for Care of Preterm Infants Receiving Non-invasive Ventilation (NIV)

November 13, 2019 updated by: Chan Sin Yee, Chinese University of Hong Kong

A Before and After Study for Development, Implementation, and Evaluation of a Clinical Practice Guideline for Care of Preterm Infants Receiving Non-invasive Ventilation (NIV)

Non-invasive ventilation (NIV) is increasingly used for supporting preterm infants with respiratory distress in the Neonatal Intensive Care Unit (NICU), and the incidence for nasal injury including skin redness or breakdown associated with pressure from the nasal interfaces is found in infants receiving this support. Risk is found higher in preterm infants than term infants due to the smaller gestation age and lower birth weight. Thus, the study aims to develop, implement, and evaluate an evidence-based practice guideline (the guideline) for preterm infants receiving NIV in the NICU. With the implementation of this guideline, it helps to promote comfort to infants receiving NIV, and at the same time to minimize complications associated with NIV.

Study Overview

Detailed Description

A workgroup is formed in the NICU to provide expert opinions in the process of development, implementation, and evaluation of the guideline. It consists of five nurses, one neonatologist and one physiotherapist. After that, 16 evidence-based articles were identified in several scientific databases, and practices in the guideline are developed after reviewed and appraised the articles.

Interventions in the guideline involve six components as

  1. choice of "right" nasal interfaces, in which the "right" size of nasal interface either short binasal prongs or nasal mask is chosen according to the size of the infant's nose and distance between two nasal nares. In addition, the "right" size of bonnet using to anchoring the ventilator tubing is also selected according to the size of infant's head.
  2. use of skin protective dressing, in which the hydrocolloid dressing is used to cover the skin areas underneath the nasal interface and anchoring straps;
  3. alternate the nasal interfaces from the short binasal prongs to nasal mask every 6 hours;
  4. positioning the infants regularly for 4-6 hours, at optimal developmental body position but avoid prone position, and well supporting the devices to prevent displacement and traction onto the infant's skin after changed position;
  5. supportive care including to wet the prongs with sterile water or saline before inserting into the nasal nares, to clean the infant's faces and nasal areas daily, to wipe away any water condensate over infant's nasal areas every 4-6 hours, to gently massage the areas during removal of the nasal interfaces or devices for examination at every routine care, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning, to provide adequate humidification to the ventilation circuit, to remove water condensate in the interfaces and ventilator circuit, to aspirate air from the gastric tube before every tube feeding to relieve abdominal distension;
  6. regular assessments on infants receiving NIV for pain level by Neonatal Pain, Agitation and Sedation Scale, intact of skin integrity for the areas in contacting with the nasal interfaces and devices of NIV, and to rate the severity of injury by the staging system from National Pressure Ulcer Advisory Panel.

The study includes two periods of "pre-implementation" and "post-implementation". In the pre-implementation period, all infants receiving NIV will be providing the usual care including choice of nasal interfaces in which larger or smaller interfaces may be given to the infant, use of skin protective dressing, positioning which is not restricted to the frequency of turning or types of position, supportive care of providing humidification to the ventilator circuit, oral care and avoiding of unnecessary nasal suctioning, removing of water condensate in the ventilator circuit, aspirating of air before alternate tube feeding.

A one-month training will be given to nurses working in the NICU after completion of the pre-implementation period. The training contains a dialect lecture, video demonstration of care, and scenario discussion.

After completion of the one-month training, the post-implementation period will be commenced, and the care in the guideline will be provided to infants receiving NIV.

Data collection on infant participants and nurses will be conducted during the study period.

Data analysis will be performed to evaluate the effectiveness of the guideline as well as the increase of nurses' knowledge in care of infants receiving NIV and their compliances to the guideline.

Study Type

Interventional

Enrollment (Anticipated)

176

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Janita Chau, Professor
  • Phone Number: +852-39436226

Study Locations

      • Hong Kong, Hong Kong
        • Recruiting
        • Queen Elizabeth Hospital
        • Contact:
        • Principal Investigator:
          • Sin Yee Chan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • the infant born before 37 completed weeks of gestation age
  • receiving or started NIV via nasal prong or nasal mask at the supports as
  • continuous positive airway pressure
  • non-invasive intermittent positive pressure ventilation
  • neural adjusted ventilatory assisted ventilation

Exclusion Criteria:

  • infants with the chromosomal abnormalities (e.g. Pierre Robin Sequence)
  • complex heart problems (e.g. transposition of great arteries, Tetralogy of Fallot, Coarctation of Aorta)
  • severe respiratory disorders/diseases (e.g. diaphragmatic hernia, tracheoesophageal fistula, cystic fibrosis, congenital cystic adenomatoid malformation)
  • craniofacial anomalies (e.g. bilateral cleft lip,cleft palate, choanal atresia)
  • congenital skin disorders (e.g. collodion baby)
  • severe acute conditions (e.g. necrotizing enterocolitis, pneumothorax, intraventricular haemorrhage, severe sepsis)
  • parents or legal guardian refuse to join the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Pre-implementation study group
Preterm infants receiving NIV before the implementation of the guideline
Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
Other Names:
  • Usual care
Other: Post-implementation study group
Preterm infants receiving NIV after the implementation of the guideline

Interventions in the guideline involve six components as

  1. choice of "right" nasal interfaces and bonnet
  2. use of skin protective dressing
  3. alternate the nasal interfaces every 6 hours;
  4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction
  5. supportive care with more new interventions
  6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV
Other Names:
  • care bundle of the guideline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
nasal injury
Time Frame: receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
infant's severity of nasal injury rated by the staging system from National Pressure Ulcer Advisory Panel
receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
pain level
Time Frame: receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
infant's pain level rated by the Neonatal Pain, Agitation and Sedation Scale (N-PASS) with minimum score at 0 and maximum score at 11 for preterm < 30 weeks & 10 for infants > or = 30 weeks. To study whether the interventions of the guideline can promote comfort for preterm infants receiving NIV, by studying indirectly on the pain level. For each infant participant, baseline of pain level will be obtained at the beginning of NIV, then pain score will be assessed every shift or every routine care (at least 4 hours) if the baseline score >3. If the pain score reduce or remain unchanged after implementation of the guideline, it shows the comfort of the infants receiving NIV
receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
activity level
Time Frame: receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
infant's activity level including sleep, active, quiet, irritable and unresponsive evaluated in hourly nursing assessment
receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
body weight
Time Frame: receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
infant's body weight weighed by the baby weight scale every alternate day
receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
abdominal girth
Time Frame: receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
infant's abdominal girth by the measuring tape every morning before feeding
receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
knowledge level of caring infants receiving NIV
Time Frame: once before the training, once just after the training, once at 12-week after completion of the one-month training in the NICU
self-developed questions as "pre-test" and "post-test" to assess nurses' knowledge of caring infants receiving NIV, the minimum score of the test is 0 and maximum is 10, the differences between the score obtained in "pre-test" and "post-test" indicates any increase of knowledge level of caring infants receiving NIV
once before the training, once just after the training, once at 12-week after completion of the one-month training in the NICU
Compliance to the guideline
Time Frame: once as baseline record in the pre-implementation period, once at 12-week and once at 24-week since the commencement of post-implementation period
self-developed audit tool to assess nurses' compliance to the guideline
once as baseline record in the pre-implementation period, once at 12-week and once at 24-week since the commencement of post-implementation period
ventilation day
Time Frame: receiving ventilation support through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
total ventilation days for infant receiving NIV and receiving invasive ventilation before changed to NIV
receiving ventilation support through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
Efficacy of NIV
Time Frame: receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group
study the total ventilation day for infants receiving NIV, and any failure of NIV as indicated by infant requiring intubation for the invasive ventilation within 24-hour after receiving NIV
receiving NIV through study period completion, an average of 6 months for pre-implementation group, and 8 months for post-implementation group

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sin Yee Chan, The Queen Elizabeth Hospital
  • Study Chair: Janita Chau, Professor, Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 2, 2019

Primary Completion (Anticipated)

December 31, 2020

Study Completion (Anticipated)

December 31, 2020

Study Registration Dates

First Submitted

November 10, 2019

First Submitted That Met QC Criteria

November 13, 2019

First Posted (Actual)

November 18, 2019

Study Record Updates

Last Update Posted (Actual)

November 18, 2019

Last Update Submitted That Met QC Criteria

November 13, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Noninvasive Ventilation

Clinical Trials on Usual care to infants receiving NIV

3
Subscribe